Bioxytran
Bioxytran is a clinical stage biopharmaceutical company dedicated to developing innovative platform technologies in Glycovirology, Hypoxia, and Degenerative Diseases. Their mission is to eliminate viruses and extend lifespan through carbohydrate drug design, with a focus on treatments for hypoxic conditions, necrosis, and viral infections such as COVID-19. They develop drugs like BXT-25, a molecule that delivers oxygen to tissues and can penetrate the blood-brain barrier, and are working on galectin inhibitors to combat viruses like SARS-CoV-2. The company emphasizes high ethical standards, scientific innovation, and has a pipeline of products targeting various medical conditions.
Industries
Nr. of Employees
small (1-50)
Bioxytran
233 Needham Street, Suite 300, Newton, MA, 02464
Products
Oral galectin‑binding polysaccharide tablet (oral antiviral candidate)
An oral chewable polysaccharide formulation designed to bind conserved lectin/galectin domains on viral surface proteins to inhibit entry; advanced into early clinical evaluation and reported in peer-reviewed studies.
Intravenous galectin‑binding formulation (systemic antiviral candidate)
Parenteral formulation intended for systemic exposure in severe viral disease to modulate immune responses and reduce pathological immune cell trafficking.
Glyco‑polymer intravenous oxygen carrier (nanoscale oxygen therapeutic)
Intravenous oxygen carrier composed of modified heme/hemoglobin conjugated to co‑polymer matrices designed to transport and release oxygen to ischemic tissues; advanced through preclinical testing and supported by intellectual property filings.
Glyco‑polymer wound oxygenation and regenerative formulations (IV/topical)
Modified heme/co‑polymer formulations and topical preparations intended to improve oxygenation of chronic wounds and accelerate healing in ischemic ulcerations.
Oral galectin‑binding polysaccharide tablet (oral antiviral candidate)
An oral chewable polysaccharide formulation designed to bind conserved lectin/galectin domains on viral surface proteins to inhibit entry; advanced into early clinical evaluation and reported in peer-reviewed studies.
Intravenous galectin‑binding formulation (systemic antiviral candidate)
Parenteral formulation intended for systemic exposure in severe viral disease to modulate immune responses and reduce pathological immune cell trafficking.
Glyco‑polymer intravenous oxygen carrier (nanoscale oxygen therapeutic)
Intravenous oxygen carrier composed of modified heme/hemoglobin conjugated to co‑polymer matrices designed to transport and release oxygen to ischemic tissues; advanced through preclinical testing and supported by intellectual property filings.
Glyco‑polymer wound oxygenation and regenerative formulations (IV/topical)
Modified heme/co‑polymer formulations and topical preparations intended to improve oxygenation of chronic wounds and accelerate healing in ischemic ulcerations.
Services
Design and conduct of Phase I/II randomized and non-randomized clinical studies for antiviral and oxygen therapeutic candidates, including endpoint selection, trial operations, data analysis, and manuscript preparation.
Preclinical testing of oxygen therapeutics and antiviral candidates using established ischemia, hemorrhagic-shock and infectious disease models to generate translational efficacy and safety data supporting regulatory filings.
Negotiation and execution of licensing agreements, joint ventures and supply partnerships to secure GMP raw materials and scale manufacturing of therapeutic candidates.
Design and conduct of Phase I/II randomized and non-randomized clinical studies for antiviral and oxygen therapeutic candidates, including endpoint selection, trial operations, data analysis, and manuscript preparation.
Preclinical testing of oxygen therapeutics and antiviral candidates using established ischemia, hemorrhagic-shock and infectious disease models to generate translational efficacy and safety data supporting regulatory filings.
Negotiation and execution of licensing agreements, joint ventures and supply partnerships to secure GMP raw materials and scale manufacturing of therapeutic candidates.
Expertise Areas
- Glycan-based antiviral and galectin antagonist therapeutics
- Intravenous nanoscale/acellular oxygen therapeutics
- Glyco‑polymer and co‑polymer biomaterials
- Preclinical efficacy and safety evaluation in animal models (ischemia, shock, infection)
Key Technologies
- Glycan-based viral entry inhibitors
- Galectin antagonist therapeutics
- Glyco‑polymers and co‑polymers for biologics
- Nanoscale/acellular oxygen carrier platforms
News & Updates
The Heme foundation partners with Bioxytran in a $10 million joint venture to develop a universal oxygen carrier using GMP quality camel hemoglobin.
Validation of technology that measures oxygenation uptake during strokes, with insights for ischemic stroke and neurodegenerative diseases.
The antiviral PHM23 was included in a grant submission to the USDA’s HPAI Poultry Innovation Grand Challenge.
An article discussing Bioxytran's innovative oxygen delivery technology for stroke treatment.
FDA Clearance of ProLectin-M IND Application
Bioxytran received FDA clearance to initiate clinical trials of ProLectin-M for COVID-19 treatment.
Broad Patent Coverage on 60+ Viruses
The US Patent and Trademark Office published a patent application covering antiviral complex carbohydrate drugs for over 60 viruses.
The Heme foundation partners with Bioxytran in a $10 million joint venture to develop a universal oxygen carrier using GMP quality camel hemoglobin.
Validation of technology that measures oxygenation uptake during strokes, with insights for ischemic stroke and neurodegenerative diseases.
The antiviral PHM23 was included in a grant submission to the USDA’s HPAI Poultry Innovation Grand Challenge.
An article discussing Bioxytran's innovative oxygen delivery technology for stroke treatment.
FDA Clearance of ProLectin-M IND Application
Bioxytran received FDA clearance to initiate clinical trials of ProLectin-M for COVID-19 treatment.
Broad Patent Coverage on 60+ Viruses
The US Patent and Trademark Office published a patent application covering antiviral complex carbohydrate drugs for over 60 viruses.